Jaime Vanourny, MD
Dermatology · Gastonia, NCNPI 1508028093
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,367 of the $13,166 with a category attached, or 78.7%. 34 manufacturers reported payments, led by Johnson & Johnson at 27.2% of the total. Reporting peaked in 2024 at $5,301 and has fallen 61.7% since, to $2,032 in 2025.
Across 570 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- AbbVie$2K
- UCB, Inc.$881
- Sanofi$624
- Lilly USA, LLC$619
- Galderma Laboratories, L.p.$615
- plus $5K from 28 others
Across 18 payments — averaging $1100.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$19K
- Sanofi$478
What the payments were for
- Consulting fees$2,72821%
- Food & beverage$10,36779%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $3,586 |
| AbbVie(2 entities) | 132 | $2,336 |
| UCB, Inc. | 29 | $881 |
| Sanofi | 30 | $624 |
| Lilly USA, LLC | 47 | $619 |
| Galderma Laboratories, L.p. | 42 | $615 |
| Sun Pharmaceutical Industries Inc. | 33 | $586 |
| E.r. Squibb & Sons, L.L.C. | 56 | $548 |
| Pfizer | 32 | $529 |
| Incyte Corporation | 26 | $461 |
| LEO Pharma Inc. | 21 | $442 |
| Regeneron Healthcare Solutions, Inc. | 13 | $421 |
| Novartis | 19 | $339 |
| Boehringer Ingelheim | 11 | $223 |
| Merz North America, Inc. | 1 | $162 |
| Amgen | 8 | $159 |
| Dermavant Sciences, Inc. | 6 | $108 |
| Fresenius Kabi USA, LLC | 4 | $80 |
| Genentech USA, Inc. | 4 | $65 |
| Organon | 6 | $59 |
| Almirall LLC | 2 | $41 |
| Sandoz | 2 | $39 |
| Mentor Worldwide LLC | 1 | $38 |
| EPI Health, LLC | 1 | $28 |
| Mayne Pharma Commercial LLC | 2 | $26 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Journey Medical Corporation | 1 | $18 |
| Strata Skin Sciences, Inc. | 2 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Botanix SB Inc | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,166 in reported general payments places this provider in the 85th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $254,229 |
| OtezlaApremilast | 27 | $152,584 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $148,928 |
| Humira PenAdalimumab | 13 | $92,060 |
| Dupixent PenDupilumab | 24 | $90,412 |
| Dupixent SyringeDupilumab | 11 | $41,422 |
| Fluorouracil | 69 | $4,183 |
| Metronidazole | 53 | $2,467 |
| Ketoconazole | 160 | $2,061 |
| Calcipotriene | 11 | $1,745 |
| Clobetasol Propionate | 50 | $1,486 |
| Desonide | 20 | $1,452 |
| ValacyclovirValacyclovir Hcl | 74 | $1,158 |
| Clindamycin Phosphate | 25 | $1,072 |
| Imiquimod | 34 | $1,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $159 | $152,58427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Gastonia
- Steven FeldmanWinston Salem$3.4M
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- George MagelHickory$554K
- Muneeb ShahClinton$451K
- John SoderbergCary$398K
- Rosalyn GeorgeWilmington$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.